Compare TFPM & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFPM | EWTX |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 2.5B |
| IPO Year | N/A | 2021 |
| Metric | TFPM | EWTX |
|---|---|---|
| Price | $32.61 | $23.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $32.33 | ★ $34.13 |
| AVG Volume (30 Days) | 590.7K | ★ 1.8M |
| Earning Date | 02-18-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $344,001,000.00 | N/A |
| Revenue This Year | $42.63 | N/A |
| Revenue Next Year | $11.85 | N/A |
| P/E Ratio | $33.07 | ★ N/A |
| Revenue Growth | ★ 39.55 | N/A |
| 52 Week Low | $15.05 | $10.60 |
| 52 Week High | $35.86 | $30.48 |
| Indicator | TFPM | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 51.51 |
| Support Level | $33.07 | $23.95 |
| Resistance Level | $34.42 | $27.40 |
| Average True Range (ATR) | 1.24 | 2.32 |
| MACD | -0.31 | -0.07 |
| Stochastic Oscillator | 16.54 | 52.88 |
Triple Flag Precious Metals Corp is a streaming and royalty company focused on precious metals. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Mexico, Mongolia, Peru, South Africa, and the United States. Its diversified portfolio of streams and royalties comprises long-life mining assets, including the Northparkes copper-gold mine in Australia, the Cerro Lindo polymetallic mine in Peru, the Fosterville gold mine in Australia, the Buritica gold mine in Colombia, and the Impala Bafokeng Operations in South Africa among others. A majority of its revenue is derived through its interests in various gold streams. Geographically, the company derives maximum revenue from Australia, followed by Peru and other regions.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.